These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 37004598)
1. Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach. Gordon S; Chan DLH; Bernard EJ; Eslick ME; Willowson KP; Roach PJ; Engel AF; Maher R; Clarke SJ; Agarwal V; Yasmin L; De Silva M; Mascall S; Conner A; Nevell D; Pavlakis N; Bailey DL J Cancer Res Clin Oncol; 2023 Aug; 149(10):7717-7728. PubMed ID: 37004598 [TBL] [Abstract][Full Text] [Related]
2. Salvage peptide receptor radionuclide therapy with [ van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116 [TBL] [Abstract][Full Text] [Related]
3. Peptide Receptor Radionuclide Therapy with Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949 [TBL] [Abstract][Full Text] [Related]
4. Prospective observational study of Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803 [TBL] [Abstract][Full Text] [Related]
5. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? Harris PE; Zhernosekov K Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of peptide receptor radionuclide therapy with Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603 [No Abstract] [Full Text] [Related]
7. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Parghane RV; Talole S; Prabhash K; Basu S Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500 [TBL] [Abstract][Full Text] [Related]
8. Personalized Del Prete M; Buteau FA; Arsenault F; Saighi N; Bouchard LO; Beaulieu A; Beauregard JM Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):728-742. PubMed ID: 30506283 [TBL] [Abstract][Full Text] [Related]
9. Personalized Del Prete M; Buteau FA; Beauregard JM Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189 [TBL] [Abstract][Full Text] [Related]